Results 71 to 80 of about 215,011 (302)

Efficacy of Inebilizumab in N‐MOmentum Trial Participants With or Without Prior Immunosuppressants

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT This post hoc analysis examined the impact of prior immunosuppressants on the long‐term efficacy and safety of inebilizumab, a cluster of differentiation 19+ B‐cell–depleting monoclonal antibody, in participants with aquaporin‐4–seropositive neuromyelitis optica spectrum disorder from the N‐MOmentum trial (NTC02200770).
Bruce A. C. Cree, Beatrice Suero, Sarah Walsh, Romain Marignier, John W. Lindsey, Ho Jin Kim, Dewei She, Daniel Cimbora, Dustin Cavida, Friedemann Paul   +9 more
wiley   +1 more source

Progressive multifocal leukoencephalopathy after immunochemotherapy: a case report highlighting pembrolizumab limitations [PDF]

Precision and Future Medicine
A 55-year-old woman with stage IV follicular lymphoma developed progressive multifocal leukoencephalopathy (PML) during rituximab maintenance therapy following bendamustine-rituximab induction.
Dayeon Seo, Seoung Wan Chae, Kyung Hoon Lee, Du-Young Kang, Yun-Gyoo Lee   +4 more
doaj   +1 more source

Human Pegivirus Encephalitis With Brain Detection and Response to Sofosbuvir Ledipasvir

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Human pegivirus (HPgV‐1) has been associated with severe encephalomyelitis in immunocompromised patients. Its neurological spectrum remains poorly defined. We report a slowly progressive encephalitis in a person living with well‐controlled HIV, characterized by white matter abnormalities and inflammatory cerebrospinal fluid (CSF). HPgV RNA was
Antoine Moulignier, Françoise Heran, Francis Lallemand, Pierre Bourdillon   +3 more
wiley   +1 more source

Drug therapy of primary biliary diseases: classical and modern strategies [PDF]

, 2013
Definition: Primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC) are both cholestatic liver diseases. A common feature of these disorders is the accumulation of bile acids in the liver and blood, presumably because of decreased ...
Leuschner, Ulrich, Schlichting, Julia
core   +1 more source

Integrated PANoptosis Profiling Identifies Immunosuppressive Subtypes and a Prognostic Signature With Functional Validation of MLKL in Glioblastoma

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective The prognosis of glioblastoma (GBM) remains highly unfavorable, largely due to high tumor heterogeneity and an immunosuppressive microenvironment. However, the functional role of PANoptosis in this context is poorly understood. Methods Patients were stratified via K‐means clustering. A risk score model was constructed using prognosis‐
Langfei Tian, Minghui Zhao, Yuanbo Hu, Kaiyue Wang, Haiguang Liu, Zetong Bai, Kebin Zheng   +6 more
wiley   +1 more source

Modern immunosuppression [PDF]

, 2017
\ua9 2017. Organ transplantation provides both life-saving and life-enhancing function for patients suffering from end-stage organ failure. Transplantation has only been possible due to the advances in immunosuppression.
Wilson C, Figueiredo RS
core  

Photodynamic Therapy–Induced Immunosuppression in Humans Is Prevented by Reducing the Rate of Light Delivery [PDF]

, 2011
Photodynamic therapy (PDT) of non-melanoma skin cancers currently carries failure rates of 10–40%. The optimal irradiation protocol is as yet unclear.
Georgia A. Frost, Halliday, Gary M., Gary M. Halliday, Damian, Diona L., Diona L. Damian, Frost, Georgia A.   +5 more
core   +1 more source

CD3+ T-cell count prediction for anti-thymocyte globulin treatment monitorization in kidney transplant recipients: a machine learning model

Frontiers in Medicine
Background and aimAntithymocyte globulin (ATG) therapy is conventionally monitored by measuring peripheral blood CD3+ T-cell counts. However, CD3+ T-cell quantification requires flow cytometry and may not be routinely available in centers.
Ahmet B. Ak, Hayri K. Goren, Nuri B. Hasbal, Nur I. Genc, Sidar Copur, Lasin Ozbek, Burak Kocak, Burak Kocak, Adrian Covic, Mehmet Kanbay, Mehmet Kanbay   +10 more
doaj   +1 more source

Disease Course After Anti‐CD20 Discontinuation in Secondary Progressive Multiple Sclerosis—A Multicenter Long‐Term Longitudinal Study

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To describe long‐term outcomes after anti‐CD20 discontinuation in selected patients with secondary progressive multiple sclerosis (SPMS) who remained without subsequent disease‐modifying therapy (DMT). Methods We retrospectively analyzed data from four centers in Austria and Switzerland.
Ferdinand Otto, Dariia Kliushnikova, Richard Friedrich Radlberger, Sinan Yasaroglu, Tobias Moser, Andrea Harrer, Kitty Kratzer, Wolfgang Hitzl, Christiane Gradl, Martin Schmidauer, Patrick Roth, Harald Hegen, Peter Wipfler   +12 more
wiley   +1 more source

Cancer outcomes in patients requiring immunosuppression in addition to corticosteroids for immune‐related adverse events after immune checkpoint inhibitor therapy [PDF]

, 2020
AIM:To examine the cancer-specific outcomes for patients who experience immune-related adverse events requiring immunosuppression beyond corticosteroids.
Burdett, N., Hsu, K., Brown, M.P., Kerri Beckmann, Xiong, L., Beckmann, K., Libo Xiong, Tapia-Rico, G., Michael P. Brown, Karapetis, C., Nikki Burdett, Gonzalo Tapia‐Rico, Kristin Hsu, Christos Karapetis   +13 more
core   +1 more source